Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Cipla
Teva
US Department of Justice
Chinese Patent Office
QuintilesIMS
Boehringer Ingelheim
Merck
Daiichi Sankyo

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075136

« Back to Dashboard
NDA 075136 describes VERAPAMIL HYDROCHLORIDE, which is a drug marketed by Glenmark Generics, Mylan, Luitpold, Actavis Elizabeth, Pliva, Sandoz, Watson Labs, Exela Pharma Scs Llc, Sun Pharm Inds Inc, Ivax Sub Teva Pharms, Marsam Pharms Llc, Hospira, Warner Chilcott, Abraxis Pharm, Intl Medication, Par Pharm, Cadila Pharms Ltd, Apotex Corp, Heritage Pharms Inc, Mutual Pharm, Bedford, Sun Pharm Inds, Solopak, and Smith And Nephew, and is included in fifty-four NDAs. It is available from thirty-seven suppliers. Additional details are available on the VERAPAMIL HYDROCHLORIDE profile page.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for NDA: 075136

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 075136

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
SOLUTION;INTRAVENOUS 075136 ANDA Hospira, Inc. 0409-9633 0409-9633-05 10 CARTON in 1 CONTAINER (0409-9633-05) > 1 SYRINGE, PLASTIC in 1 CARTON > 4 mL in 1 SYRINGE, PLASTIC
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
SOLUTION;INTRAVENOUS 075136 ANDA General Injectables & Vaccines, Inc 52584-633 52584-633-05 1 BOX in 1 BAG (52584-633-05) > 1 SYRINGE in 1 BOX > 4 mL in 1 SYRINGE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength5MG/2ML (2.5MG/ML)
Approval Date:Oct 20, 1998TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Fuji
Baxter
Express Scripts
Chinese Patent Office
AstraZeneca
Julphar
Queensland Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot